Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study

Kamath, Jayesh; Feinn, Richard; Winokur, Andrew

doi:10.1007/s00520-011-1268-8

Cited by 19 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In further exploration at data extraction, seven more studies were rejected for one or more of the reasons listed above. The final number of trials included for qualitative analysis was 30 22–51 (figure 1). In 11 trials, some of the data needed for meta-analysis were not published in the trial paper; therefore, we sought contact with authors.…”

Section: Resultsmentioning

confidence: 99%

Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

Rojí

Stone

Ricciardi

et al. 2020

BMJ Support Palliat Care

View full text Add to dashboard Cite

BackgroundCancer-related fatigue (CRF) is one of the most distressing symptoms experienced by patients. There is no gold standard treatment, although multiple drugs have been tested with little evidence of efficacy. Randomised controlled trials (RCTs) of these drugs have commented on the existence or size of the placebo response (PR). The objective of this systematic review was to establish the magnitude of the PR in RCTs of drugs to relieve CRF and to identify contributing factors.MethodRCTs were included in which the objective was to treat CRF. A meta-analysis was conducted using the standardised mean change (SMC) between baseline and final measurement in the placebo group. To explore factors that may be associated with the PR (eg, population or drug), a meta-regression was undertaken. Risk of bias was assessed using the revised Cochrane tool.ResultsFrom 3916 citations, 30 relevant RCTs were identified. All had limitations that increased their risk of bias. The pooled SMC in reduction in fatigue status in placebo groups was −0.23 (95% confidence intervals −0.42 to −0.04). None of the variables analysed in the meta-regression were statistically significant related to PR.ConclusionThere is some evidence, based on trials with small samples, that the PR in trials testing drugs for CRF is non-trivial in size and statistically significant. We recommend that researchers planning drug studies in CRF should consider implementing alternative trial designs to better account for PR and decrease impact on the study results.

show abstract

Section: Resultsmentioning

confidence: 99%

Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

Rojí

Stone

Ricciardi

et al. 2020

BMJ Support Palliat Care

View full text Add to dashboard Cite

show abstract

“… 56 Preliminary data highlight the role of thyrotropin-releasing hormone in CRF treatment and improvement in QoL with patients’ manifestations of exhaustion, with exhaustion improving within few hours of treatment. 57 However, further studies are needed to confirm these results. There is much evidence on erythropoiesis-stimulating agents (ESA) in ameliorating CRF in anemic patients (also with LC) during chemotherapy.…”

Section: Methodsmentioning

confidence: 94%

Fatigue in lung cancer patients: symptom burden and management of challenges

Carnio¹,

Stefano²,

Novello³

2016

LCTT

View full text Add to dashboard Cite

Lung cancer (LC) remains the most common cause of cancer death in several countries across the world. Fatigue is the most frequently reported symptom in LC patients throughout the entire course of disease, and all international guidelines recommend early screening for cancer-related fatigue (CRF) and symptoms that can affect patients’ quality of life. In patients with LC, fatigue belongs to the symptom cluster of pain, depression, and insomnia, which are commonly observed simultaneously, but are typically treated as separate although they may have common biological mechanisms. The treatment of CRF remains one of the difficult areas in the oncology field: scarce evidence supports pharmacological therapies, while some interesting data arising indicates alternative remedies and physical exercise seem to be one of the most effective approaches for CRF at any stage of LC.

show abstract

“…TAL is a thyrotropin-releasing hormone (TRH) analog. TRH reduced CRF in a study of eight patients [30], but required i.v. administration of a 0.5 or 1.5 mg dose for this effect.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays

Dougherty

Springer

Cullen

et al. 2019

Behavioural Brain Research

View full text Add to dashboard Cite

Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study

Abstract: TRH administration was efficacious, safe, and tolerable in the treatment of CF with a positive impact on quality of life. These results provide a crucial impetus for pursuing TRH therapeutics to treat CF.

Cited by 19 publications

References 31 publications

Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

Fatigue in lung cancer patients: symptom burden and management of challenges

Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays

Contact Info

Product

Resources

About